Key Takeaways
- A quarter derailed by policy and demand: Revenue fell 9% YoY as a 22% customs duty hike on crude vegetable oils collided with a sharp drop in paint-sector demand from mid-August, forcing the company to absorb costs and compressing EBITDA margin to 6.28%.
- Isostearic acid is the lone bright spot: The highest-priced product in the basket is gaining customer traction, with shipments that began in January 2024 now targeting the higher-value cosmetics market and a volume ramp-up expected from Q4.
- Pricing power is structurally absent in dimer acid: The company’s formula is pegged to Chinese import landed cost plus ~8.25% duty, so it cannot pass on raw material inflation without ceding its 65–70% domestic share to Chinese competitors.
- A new product cycle is years, not quarters, away: A pilot plant for a novel product using alternate raw material begins construction in FY26, with 40,000 tons of capacity earmarked, but economics and timelines depend entirely on pilot yields.
- What to watch next quarter: Whether Q3 performance can be held at Q2 levels as management aims, any movement on the government duty reversal, and the pace of Isostearic acid customer approvals heading into the hoped-for Q4 ramp.
The Policy Shock: Customs Duty & Its Cascading Effects
- 22% duty hike in September 2024 on certain crude vegetable oils directly raised raw material costs for dimer acid production, with the impact hitting in the last 15 days of the quarter.
- No pass-through mechanism exists because the company’s dimer acid pricing is formulaically tied to the CIF landed cost of Chinese dimer acid plus non-cenvatable duty (~8.25%). Chinese import prices and the 7.5% duty on dimer imports remained unchanged, so any price increase above that formula would reverse the current 65–70% domestic market share to 35%, with Chinese imports taking the rest.
- Cost absorption is the chosen strategy to retain market share while management waits for a government reversal, which it believes is inevitable once farmers sell their oilseed produce and soya oil price inflation (from ~₹100 to ₹130–134) becomes politically untenable.
- Gross margin collapsed from 30% to 24% QoQ, driven by the duty increase plus paint-sector buyers bargaining aggressively amid weak demand, a pressure that management says is continuing “in a big way.”
Rajen Jhaveri: “But this government notification has created a havoc. Now, we will have to wait for this reversal of government and of course, paint, this demand from paint.”
Demand: The Paint Sector Freeze
- Decorative paint demand fell sharply from mid-August, with management citing Asian Paints’ own CEO sounding pessimistic about the sector for the coming six months.
- Asian Paints is the dominant customer, accounting for approximately two-thirds of total sales, and management describes it as unmatched in fair dealing and timely payment, making diversification within the paint sector unattractive at lower margins.
- Volume growth guidance of 10–15% for FY25 is not formally withdrawn but management concedes it will be difficult to achieve given Q2 underperformance and likely Q3 weakness; the company will try to achieve growth in Q4.
- Q3 is already half-lost: 45 days of the quarter have passed with elevated raw material costs and no ability to pass them on, so margins cannot be expected to improve from Q2 levels. Management’s goal is to hold performance at par with Q2.
- Paint demand recovery is hoped for from Q4 (Jan–Mar 2025), based on India’s large population and the assumption that the current weakness is temporary, though no concrete demand signals are cited.
Rajen Jhaveri: “In paint sector, there is no customer like Asian Paints Ltd. Let me tell you upfront. In terms of everything. fair dealing, timely payment, etc. everything, everything.”
Isostearic Acid: The Margin Lifeline
- Isostearic acid is the highest-priced product in the entire basket, made by upgrading monobasic acid, a co-product of dimer production. Only four companies globally are known to make it.
- Shipments began in January 2024 in a small way, initially targeting lubricants, and are now pivoting to the costlier cosmetics market, which requires semi-pharma US FDA-level approvals but fetches higher value.
- Volume ramp-up is gradual by design: even after approval, the ordering process is slow (initially one container), and the full chain from sample approval to consistent quality satisfaction and full orders involves 45-day shipping to the US and customer testing cycles.
- Q3 volumes are expected to be similar to Q2; significant volume growth is expected from Q4 (Jan–Mar 2025) as more approvals come in, with “quite good volume” targeted by the beginning of next financial year.
- Isostearic acid expansion is structurally linked to dimer acid: more Isostearic acid requires more monobasic acid, which simultaneously produces more dimer acid, so growth in one forces growth in the other. Management is already working on how to increase capacity beyond 3,000 tons if demand rises.
- Margin potential even without duty reversal: Isostearic acid alone has the ability to lift margins up to 12% if paint demand revives and approvals are received, though the current composite margin sits at 6%.
- Management declined to disclose Isostearic acid turnover or volume, citing competitive intelligence concerns, as unlisted Indian competitors listen to the call and use the information for business decisions.
Rajen Jhaveri: “Compared to lubricants, the application for cosmetics can fetch a somewhat higher value. In absolute terms, it is the highest priced product of our entire product basket.”
Business Model & Competitive Position
- The company operates like a petroleum refinery: it purchases a waste product from vegetable oil refineries and upgrades it into different fatty acids, with profitability being a composite of all products rather than attributable to any single one.
- Dimer acid quality now matches Chinese product, so the only competitive lever is price. If Fairchem prices above Chinese landed cost, the market share split could invert from 65–35 in Fairchem’s favor to 35–65 against it.
- Capacity utilization stands at 75% of the 80,000-ton capacity for present activities, leaving only 25% spare capacity for demand increases. An additional 40,000 tons of capacity is earmarked for new products under development.
- Tocopherol has been strategically de-emphasized: the global market is controlled by three giants (Cargill, ADM, Kensing Solution) with over 80% share, the product is highly cyclical (management experienced a 60% overnight price drop in September 2000), and about 5–6 years ago the decision was made to focus on fatty acids instead. Tocopherol is now produced only when US customers face short supply.
- A vacant plant purchased years ago remains idle with no immediate usage plan; management prefers to absorb activities at the present plant to avoid additional setup costs, and is creating space by converting horizontal tanks to vertical tanks.
Rajen Jhaveri: “…like a petroleum refinery, which purchases brent and makes different products viz. petrol, diesel, aviation fuel, furnace oil, etc., etc., we also purchase a waste product from the vegetable oil refinery and extract different fatty acids and upgrade them.”
The New Product Pipeline: A FY26 Story
- A pilot plant for a new product using alternate raw material is the next growth vector. Laboratory-scale work is complete, a pilot plant has been purchased, and work will start with plant erection beginning in FY26 after successful pilot results.
- 40,000 metric tons of capacity is earmarked for new products; some equipment is already earmarked, with the balance to be procured after the pilot plant proves out.
- Two novel products will be made from the alternate raw material, and the company claims it will be the first in India to make these kinds of products. The raw material scope stays within the core competency of specialty oleochemicals.
- Economics are entirely unknown: whether the new product is high margin will be known only after pilot plant results, as yields are critical for margin determination. CAPEX is preliminarily estimated at ₹35–40 crore but could change depending on whether equipment is custom-made or standard.
- Management declined to disclose the application industry for the new raw material, saying revealing the application would reveal the product itself, and that competitors do more post-mortem of shared information than participants in the call.
Rajen Jhaveri: “See, then it would become, there are two things. One, it would become UPSI, more detail and another thing, just now what I said that our competitors are having more post-mortem of whatever we are sharing than the participants in this call.”
Balance Sheet & Capital Allocation
- Debt increase is an accounting artifact, not new leverage: the company previously used an Asian Paints bills discounting facility that was not booked as debt under accounting guidelines. That facility is no longer being utilized, so receivables now appear alongside short-term borrowing.
- Trade receivables rose from ₹55 crore to ₹80 crore due to two factors: the changed arrangement with Asian Paints, and Isostearic acid sales to European and US customers requiring extended credit terms. Management is not worried about recovery as these are large companies.
- Solar CAPEX of up to ₹30–35 crore may be undertaken, with land identification and title clearance as the main hurdles. Once cleared, installation should take no more than 60 days.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q3 performance floor | Hold performance at par with Q2 level | Q3 FY25 (Oct–Dec 2024) |
| Isostearic acid volume ramp | Significant volume growth; “quite good volume” targeted | Q4 FY25 (Jan–Mar 2025) |
| Paint demand recovery | Demand expected to revive | Q4 FY25 (Jan–Mar 2025), conditional |
| EBITDA margin target | 14–15% | Conditional on duty reversal, paint demand revival, and Isostearic acid approvals all falling in place |
| Pilot plant construction start | Plant erection to begin | FY26, after successful pilot plant results |
| New product CAPEX | Preliminary estimate ₹35–40 crore | Subject to change based on pilot plant yield results |
| Solar plant installation | CAPEX up to ₹30–35 crore; installation within 60 days | Conditional on land identification and title clearance |
| FY25 volume growth (10–15%) | Not formally withdrawn but acknowledged as difficult to achieve | FY25; company will try to achieve growth in Q4 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue from operations | ₹139 cr, declined 9% YoY |
| EBITDA | ₹9 cr, declined 48% YoY |
| EBITDA margin | 6.28%, vs 10.05% in H1 FY25 |
| Net profit | ₹4 cr, declined 61% YoY |
| PAT margin | 2.89% |
| H1 FY25 revenue from operations | ₹304 cr, declined 3% YoY |
| H1 FY25 EBITDA | ₹31 cr, grew 7% YoY |
| H1 FY25 net profit | ₹18 cr, grew ~9% YoY |
| Finished goods sales volume | Declined 15.60% QoQ |
| Finished goods sales value | Declined 15.90% QoQ |
| Sales volume | 14,000+ tons |
| Linoleic acid and dimer acid combined contribution | ~68-69% of sales value, vs ~67% in Q1 |
| Dimer acid contribution | ~24-25% of sales |
| Capacity utilization | 75%, annualized 60,000 tons against 80,000 tons installed capacity for present activities |
| Gross margin | 24%, down from 30% in Q1 |
| Trade receivables | ~₹80 cr (H1 FY25), up from ~₹55 cr in FY24 |
| FY25 volume growth guidance | 10-15%, not revised but difficult to achieve |
| EBITDA margin target (if conditions normalize) | 14-15% |
| Isostearic acid peak capacity value | Up to ₹150 cr at 3,000 tons per annum |
| Custom duty increase on crude vegetable oils | 22%, effective September 2024 |
| Custom duty on dimer acid imports | 7.5%, unchanged |
| Solar plant planned CAPEX | ₹30-35 cr, payback period 4-4.5 years |
| Remaining CAPEX for present activities by March 2025 | ~₹5 cr |